- Invacare press release ( NYSE: IVC ): Q3 GAAP EPS of -$0.92.
- Revenue of $170.4M (-24.0% Y/Y).
- Gross margin was 18.4%, a decrease of 850 basis points, including 510 basis points of decline related to the write-down of respiratory inventory as a result of the decision to discontinue production of respiratory products.
- SG&A expense decreased 1.4% to $55.4 million, and constant currency SG&A increased 4.5%.
- Operating loss was $33.4 million compared to a loss of $24.8 million.
- Adjusted EBITDA loss was $11.8 million, compared to positive $8.0 million.
- Free cash flow usage was $20.5 million compared to usage of $6.1 million.
For further details see:
Invacare GAAP EPS of -$0.92, revenue of $170.4M